StreetInsider.com News Articles

Form 10-K MARAVAI LIFESCIENCES For: Dec 31

Thu, 26 Feb 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260226/26070580.html

Form 10-K MARAVAI LIFESCIENCES For: Dec 31

Thu, 26 Feb 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260226/26070580.html

Maravai LifeScience Holdings Inc. (MRVI) PT Raised to $3 at Baird

Thu, 26 Feb 2026 10:04:01 -0500

Baird analyst Catherine Schulte raised the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $3.00 (from $2.00) while maintaining a Neutral rating.

Form 8-K MARAVAI LIFESCIENCES For: Feb 25

Wed, 25 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260225/26059799.html

Form 8-K MARAVAI LIFESCIENCES For: Feb 25

Wed, 25 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260225/26059799.html

Maravai LifeSciences (MRVI) Tops Q4 EPS by 3c ; Offers Guidance

Wed, 25 Feb 2026 16:04:38 -0500

Maravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $49.02 million.

GUIDANCE:

Maravai LifeSciences sees FY2026 revenue of $200-210 million, versus the consensus of $203.3 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

Maravai LifeSciences (MRVI) Tops Q4 EPS by 3c ; Offers Guidance

Wed, 25 Feb 2026 16:04:38 -0500

GUIDANCE:

Maravai LifeSciences sees FY2026 revenue of $200-210 million, versus the consensus of $203.3 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

SAN DIEGO--(BUSINESS WIRE)-- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates.

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of

Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

Wed, 25 Feb 2026 16:01:00 -0500

Organizational restructuring and operating cost reduction ahead of plan

Focus on operational excellence, revenue growth, and improving Adjusted EBITDA

Key Financial Results:

Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million;
Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of